Shareholders Equity: The sum of preferred and common equity items.
Silexion Therapeutics Corp (SLXN) had Shareholders Equity of $2.60M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-4.41M |
|
-- |
|
-- |
|
$4.41M |
|
$-4.41M |
|
$-0.01M |
|
$-4.41M |
|
$-4.41M |
|
$-4.41M |
|
$-4.41M |
|
$-4.41M |
|
$-4.41M |
|
$-4.41M |
|
$-4.40M |
|
1.33M |
|
1.33M |
|
$2.14 |
|
$2.14 |
|
| Balance Sheet Financials | |
$6.64M |
|
$0.03M |
|
$0.58M |
|
$7.21M |
|
$2.76M |
|
$1.57M |
|
$1.85M |
|
$4.61M |
|
$2.60M |
|
$2.60M |
|
|
Shareholders Equity |
$2.60M |
3.13M |
|
| Cash Flow Statement Financials | |
$-10.82M |
|
$-0.01M |
|
$15.64M |
|
$1.27M |
|
$6.08M |
|
$4.80M |
|
$0.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.41 |
|
-- |
|
-- |
|
0.38 |
|
0.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.83M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-169.50% |
|
-169.50% |
|
-61.15% |
|
-105.78% |
|
$0.83 |
|
$-8.14 |
|
$-8.14 |
|